Date: 2013-01-07
Type of information: Licensing agreement
Compound: RET, ROS1 and DEPDC1 biomarkers
Company: Qiagen (The Netherlands) Insight Genetics (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: non-small cell lung cancer (NSCLC)
Details: * On January 7, 2013, Qiagen has announced three separate agreements that add new biomarkers to its pipeline of personalized healthcare diagnostics. The second one has been concluded with the US company Insight Genetics. Qiagen has agreed to license exclusive worldwide rights from Insight Genetics Inc for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer (NSCLC).
Financial terms:
Latest news:
